The University of Southampton
University of Southampton Institutional Repository

A randomized, double-blind, placebo-controlled study of tumor necrosis factor- blockade in severe persistent asthma

Wenzel, S. E., Barnes, P. J., Bleecker, E. R., Bousquet, J., Busse, W., Dahlen, S.-E., Holgate, S. T., Meyers, D. A., Rabe, K. F., Antczak, A., Baker, J., Horvath, I., Mark, Z., Bernstein, D., Kerwin, E., Schlenker-Herceg, R., Lo, K. H., Watt, R., Barnathan, E. S. and Chanez, P. (2009) A randomized, double-blind, placebo-controlled study of tumor necrosis factor- blockade in severe persistent asthma American Journal of Respiratory and Critical Care Medicine, 179, (7), pp. 549-558. (doi:10.1164/rccm.200809-1512OC).

Record type: Article


Rationale: The treatment effect of golimumab, a human monoclonal antibody against tumor necrosis factor (TNF)-?, in severe persistent asthma is unknown.

Objectives: To assess the safety and efficacy of golimumab in a large population of patients with uncontrolled, severe persistent asthma.

Methods: From 2004 to 2006, 309 patients with severe and uncontrolled asthma, despite high-dose inhaled corticosteroids and long-acting ?2 agonists, were randomized 1:1:1:1 to monthly subcutaneous injections of placebo or golimumab (50, 100, or 200 mg) through Week 52. Coprimary endpoints were the change from baseline through Week 24 in prebronchodilator percent-predicted FEV1 and the number of severe asthma exacerbations through Week 24.

Measurements and Main Results: No significant differences were observed for the change in percent-predicted FEV1 (least squares mean: placebo, 2.44 [95% confidence interval (CI) ?0.574 to 5.461]; combined 100-mg and 200-mg, 2.91 [0.696–5.116]) or severe exacerbations (mean ± SD: placebo, 0.5 ± 1.07 vs. combined 100-mg and 200-mg 0.5 ± 0.97) through week 24. Through Week 24, 2.6% of patients treated with placebo vs. 19.5% of those treated with golimumab discontinued the study agent, and 1.3% and 7.8% discontinued study participation, respectively. An unfavorable risk–benefit profile led to early discontinuation of study-agent administration after the Week-24 database lock. Through Week 76, 20.5% of patients treated with placebo and 30.3% of patients treated with golimumab experienced serious adverse events, with serious infections occurring more frequently in golimumab-treated patients. One death and all eight malignancies occurred in the active groups.

Conclusions: Overall, treatment with golimumab did not demonstrate a favorable risk–benefit profile in this study population of patients with severe persistent asthma.

PDF 549.full[1].pdf - Other
Restricted to Repository staff only
Download (348kB)

More information

Published date: January 2009
Organisations: Clinical & Experimental Sciences


Local EPrints ID: 341520
ISSN: 1073-449X
PURE UUID: 2bea416e-a41e-43b2-bfbf-d342e11718c8

Catalogue record

Date deposited: 26 Jul 2012 14:32
Last modified: 18 Jul 2017 05:35

Export record



Author: S. E. Wenzel
Author: P. J. Barnes
Author: E. R. Bleecker
Author: J. Bousquet
Author: W. Busse
Author: S.-E. Dahlen
Author: S. T. Holgate
Author: D. A. Meyers
Author: K. F. Rabe
Author: A. Antczak
Author: J. Baker
Author: I. Horvath
Author: Z. Mark
Author: D. Bernstein
Author: E. Kerwin
Author: R. Schlenker-Herceg
Author: K. H. Lo
Author: R. Watt
Author: E. S. Barnathan
Author: P. Chanez

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.